









Markets
/
Stocks
/
nasdaq-crmd
/

CorMedix Inc

CRMD



View Detailed Chart

9.810USD

+0.160+1.66%

Close 11/28, 13:00（ET）Quotes delayed by 15 min

768.60MMarket Cap

4.73P/E TTM



CorMedix Inc

9.810

+0.160+1.66%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.66%

5 Days

+1.34%

1 Month

-13.26%

6 Months

-19.72%

Year to Date

+21.11%

1 Year

-0.51%

View Detailed Chart

TradingKey Stock Score of CorMedix Inc

Currency: USD Updated: 2025-11-28

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CorMedix Inc's Score

Industry at a Glance

Industry Ranking

68 / 159

Overall Ranking

173 / 4585

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

19.000

Target Price

+93.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CorMedix Inc Highlights

StrengthsRisks

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 66363.08% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.47M.

Overvalued

The company’s latest PE is 4.13, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 36.30M shares, increasing 9.14% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 5.07K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.50.